Journal article
Pancytopenia as a Complication of Low-Dose Methotrexate in a Septuagenarian: A Rare Presentation
CUREUS JOURNAL OF MEDICAL SCIENCE, v 12(6), e8492
07 Jun 2020
PMID: 32656010
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Methotrexate (MTX) is an antimetabolite that was initially developed as a chemotherapeutic agent to treat malignancies but later used extensively to treat rheumatological conditions. MTX-induced toxicity is dose- and duration-dependent. Myelosuppression is a rare but fatal complication of MTX that can occur even with low doses used for inflammatory conditions. Multiple factors such as age, renal impairment, and nutritional status increase the risk of developing MTX toxicity. Frequent monitoring of symptoms and lab values are the hallmarks of prompt diagnosis and prevention of complications. Clinicians should have a high degree of suspicion to diagnose pancytopenia secondary to MTX especially in patients with multiple confounding comorbidities. We present the case of a 79-year-old male who presented with mucositis and pancytopenia diagnosed to be secondary to weekly MTX for giant cell arteritis leading to anemia and septic shock causing death.
Metrics
9 Record Views
Details
- Title
- Pancytopenia as a Complication of Low-Dose Methotrexate in a Septuagenarian: A Rare Presentation
- Publication Details
- CUREUS JOURNAL OF MEDICAL SCIENCE, v 12(6), e8492
- Publisher
- SPRINGERNATURE; LONDON
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Drexel University
- Web of Science ID
- WOS:000538963200011
- Other Identifier
- 991021860768304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Rheumatology